Silexion Therapeutics
SLXN
5 hedge funds and large institutions have $613K invested in Silexion Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.49% more ownership
Funds ownership: 0% → 1.49% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
+$1.19M |
| 2 |
HF
HRT Financial
New York
|
+$105K |
| 3 |
VF
Virtu Financial
New York
|
+$31.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$17.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$17.3K |
Top Sellers
SLXN Hedge Fund Activity: Q3 2024 in Review
5 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q3 2024, worth a combined $613K.
Buyers outnumbered sellers: 5 funds opened new SLXN positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wildcat Capital Management, opening a new position worth an estimated $1.19M.
- 5 institutional investors held Silexion Therapeutics (SLXN) as of Q3 2024, up from 0 in Q2 2024.
- Funds reported $613K of Silexion Therapeutics stock for Q3 2024.
- 5 funds opened new Silexion Therapeutics positions in Q3 2024 and 0 closed out, a net change of +5 holders.
- The largest Silexion Therapeutics buyer in Q3 2024 was Wildcat Capital Management, an estimated $1.19M added.
Based on aggregated 13F filings for Q3 2024.